The need for such guidance is rooted in biology. AQP4+ NMOSD and MOGAD are antibody-mediated inflammatory conditions of the central nervous system, but they differ fundamentally in their immunopathology. AQP4 antibodies target a water channel concentrated on astrocytic endfeet, producing lesions that cluster around the ventricles, in the area postrema, and along regions of high aquaporin 4 expression. MOG antibodies, by contrast, attack a myelin surface protein, generating a distinct pattern of demyelination that often involves the optic nerves, spinal cord and, in children, the cerebral cortex. These differences translate into different imaging signatures, different disease courses and different treatment strategies, making accurate radiological interpretation a matter of clinical urgency.

Yet the panel acknowledges that the diagnostic landscape remains treacherous. Imaging features of the two diseases overlap with each other and with multiple sclerosis, lesions evolve in unpredictable ways over time, and acquisition protocols vary widely between centers. A patient presenting with optic neuritis or transverse myelitis may harbor any of these conditions, and the wrong diagnosis can lead to the wrong therapy, with potentially devastating consequences. The new recommendations therefore serve a dual purpose: standardizing practice and sharpening the differential diagnosis at the bedside.

At the heart of the document are standardized protocols. The authors define a core set of MRI sequences that should be performed in every patient, alongside optional sequences for specific clinical questions. Brain MRI, spinal cord imaging and orbital imaging each receive detailed attention, with guidance on the timing of scans at presentation, during acute attacks, and in the follow-up period. The recommendations extend the MAGNIMS framework, long established for multiple sclerosis, into these antibody-mediated diseases, creating a parallel infrastructure for image acquisition and reporting that can be implemented in routine clinical practice.

The characteristic conventional MRI findings of each disease receive careful treatment. In AQP4+ NMOSD, lesions typically affect the spinal cord over long segments, the area postrema causing intractable hiccups and nausea, periependymal surfaces of the ventricles, and the optic chiasm. In MOGAD, longitudinally extensive myelitis is also common but tends to involve the conus medullaris, while optic nerve involvement is frequently anterior and bilateral, and cortical lesions with seizures, including the FLAMES pattern of unilateral cortical FLAIR hyperintensity, point toward MOG antibodies. Recognizing these patterns helps clinicians distinguish the two diseases from each other and from multiple sclerosis, where short-segment cord lesions, central vein signs and paramagnetic rim lesions dominate.

One of the most clinically valuable sections addresses the acute attack. MRI plays a decisive role in determining whether a patient is experiencing a true relapse or a pseudo-relapse, a distinction that changes management entirely. The panel also highlights the phenomenon of radiologic lag in MOGAD, in which brain lesions may appear or evolve days to weeks after the clinical onset of an attack, meaning an early normal scan does not exclude active disease. Serial imaging during the attack window can therefore reveal lesion dynamics that a single time point misses, and the timing of follow-up scans matters as much as their content.

Post-attack recovery is another area where the recommendations break new ground. MOGAD lesions, unlike those of many other demyelinating diseases, have a striking tendency to resolve on T2-weighted images, and the panel discusses the timing and predictors of this lesion resolution. The degree of tissue recovery, visible as the fading of lesions and the relative preservation of tissue volume, carries prognostic weight and informs decisions about how aggressively to treat and how long to continue immunotherapy. Spinal cord atrophy, which correlates with disability in NMOSD, is identified as a key longitudinal measure.

Beyond conventional imaging, the document surveys the added value of non-conventional MRI techniques. Diffusion-based measures, myelin-sensitive sequences, magnetization transfer imaging and volumetric analysis can probe microstructural damage, inflammatory activity and tissue repair that standard T2 and T1 sequences cannot capture. Advanced approaches such as neurite orientation dispersion and density imaging, 7 Tesla imaging of myelin signal in normal-appearing white matter, and even indices of glymphatic system dysfunction are reviewed as research tools that may mature into clinical biomarkers. The panel also points to the emerging role of machine learning and radiomics, including deep learning models trained to distinguish MOGAD from multiple sclerosis, as a frontier for automated diagnostic support.

The recommendations confront one of the field’s most stubborn problems: seronegative NMOSD. Patients who present with the clinical and radiological phenotype of NMOSD but lack detectable AQP4 antibodies form a heterogeneous group whose classification remains uncertain, and whose response to therapy may differ from that of seropositive patients. The panel outlines the diagnostic complexity of this population and argues that novel imaging biomarkers are needed to improve classification and treatment precision, potentially allowing MRI itself to stratify patients when antibody testing is inconclusive.

Ultimately, the consensus document represents a maturing of the field. With targeted therapies now available for both AQP4+ NMOSD and MOGAD, and with growing interest in when immunotherapy can be safely discontinued, standardized imaging is no longer a luxury but a clinical necessity. By codifying what to scan, when to scan and how to interpret the results, the MAGNIMS panel has given neurologists, neuroradiologists and researchers a common language for these diseases, one that should accelerate both better individual care and the multicenter trials needed to push the field forward.

Subject of Research: Consensus recommendations for the use of MRI in diagnosing and monitoring neuromyelitis optica spectrum disorder and MOG antibody-associated disease

Article Title: Use of MRI in neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease — MAGNIMS consensus recommendations

Article References: Cortese, R., Hacohen, Y., Arrambide, G., Bianchi, A., DeLuca, G., Filippi, M., Gasperini, C., Geraldes, R., Granziera, C., Haider, L., Messina, S., Sastre-Garriga, J., Preziosa, P., Rocca, M. A., Rovira, A., Tintoré, M., Toosy, A., Tortorella, C., Vaneckova, M., … Schoonheim, M. (2026). Use of MRI in neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease — MAGNIMS consensus recommendations. Nature Reviews Neurology. https://doi.org/10.1038/s41582-026-01271-2

Image Credits: AI Generated

DOI: 10.1038/s41582-026-01271-2

Keywords: MRI, NMOSD, MOGAD, aquaporin-4 antibodies, myelin oligodendrocyte glycoprotein, demyelinating disease, neuroimmunology, MAGNIMS, optic neuritis, myelitis, diagnostic criteria, biomarkers

Discovering the neuroimaging characteristics of MOGAD is crucial because this autoimmune condition often remains underrecognized. MOGAD primarily affects myelin sheaths, leading to demyelination and a variety of neurological symptoms. Despite evolving awareness within the medical community, many practitioners still grapple with its clinical identification. The efforts of Choi and colleagues provide clarity to practitioners sifting through the myriad presentations associated with this disease.

Given the complexity of MOGAD, which frequently mimics other neurological disorders, neuroimaging plays an integral role in elucidating its features. Techniques such as MRI have proven invaluable in revealing subtle changes in the brain’s architecture associated with MOGAD. In particular, the detection of lesions in corticomedullary junctions and periventricular areas serves as a unique hallmark of MOGAD. These findings are crucial for differentiating MOGAD from conditions like multiple sclerosis or neuromyelitis optica, enabling more precise clinical management.

Choi et al. emphasize that the neuroimaging spectrum of MOGAD encompasses a wide range of cerebral syndromes, each with distinct imaging characteristics. For instance, patients may present with symptoms ranging from encephalitis to optic neuritis or even acute disseminated encephalomyelitis (ADEM). The variability in clinical presentations necessitates comprehensive neuroimaging studies to create a more robust differential diagnosis framework, ultimately aiming to minimize misdiagnosis.

Their study meticulously documented various presentations of MOGAD, with detailed analysis of the imaging findings that correlate closely with symptoms. For instance, the presence of MOG antibodies typically corresponds with specific patterns of lesions within the brain, as illustrated through diverse MRI sequences that capture both acute and chronic stages of the disease. These findings underscore the necessity of utilizing advanced neuroimaging techniques to identify key indicators of MOGAD with higher sensitivity and specificity.

One of the striking revelations from the research involves the inter-relationships between clinical syndromes and neuroimaging profiles. The patterns observed highlight the fact that different syndromic presentations might share underlying neuroimaging characteristics. For example, while optic neuritis is often associated with demyelinating lesions in the optic nerve, MOGAD can present with similar lesions but also demonstrate broader neuronal involvement across the brain, raising important questions regarding the autoimmune response’s nature in these patients.

Furthermore, the research discusses the implications of these findings for patient management. A clearer understanding of the neuroimaging spectrum allows clinicians to implement targeted therapeutic strategies that can be tailored to individual patients. By identifying the specific cerebral syndromes associated with MOGAD through neuroimaging, healthcare providers can refine their treatment approaches to include immunotherapy early in the disease course, potentially altering the disease’s trajectory.

Moreover, the study’s authors posit that the neuroimaging findings might not only facilitate diagnosis but could also serve as prognostic markers for patient outcomes. By correlating specific imaging features with clinical courses, clinicians could develop more informed expectations regarding disease progression, aiding in patient counseling and treatment planning.

In addition to clinical implications, the researchers encourage ongoing education and awareness initiatives targeting MOGAD. As understanding of the disease expands, so too does the need for widespread recognition amongst neurologists and radiologists alike. Highlighting the neuroimaging characteristics of MOGAD can foster an environment where rapid diagnosis becomes feasible, and timely interventions lead to improved patient outcomes.

Choi et al.’s findings echo the necessity for a multidisciplinary approach to MOGAD management. Neurologists, radiologists, and immunologists must collaborate to truly comprehend this complex disorder and its neuroimaging manifestations. As research into MOGAD continues to evolve, interdisciplinary discussions are essential to unravel the intricacies of its effects on the central nervous system and improve therapeutic options.

Ultimately, the study represents a significant leap forward in the understanding of MOGAD. By elucidating the neuroimaging spectrum and its associated cerebral syndromes, Choi et al. have laid a foundation for ongoing research. Future studies are likely to build upon these findings, exploring genetic, environmental, and immunological factors that may further enhance understanding of this enigmatic disorder.

Spotlighting the promising insights from this research could lead to increased dialogue within the scientific community and beyond, raising awareness of MOGAD and encouraging further exploration. Such initiatives are not only beneficial for refining diagnostic criteria but also critical in enhancing therapeutic interventions and improving overall patient care in the face of this challenging autoimmune disease.

In conclusion, the research conducted by Choi and colleagues on the neuroimaging spectrum of MOGAD represents a pivotal advancement in neurologic medicine. As the healthcare community works to unravel the complexities of autoimmune diseases, studies like this one will serve as vital resources, ensuring that medical professionals have access to the most current information to inform their practice.

Subject of Research: Neuroimaging spectrum of myelin oligodendrocyte glycoprotein antibody-associated disease with brain involvement.

Article Title: Neuroimaging spectrum of myelin oligodendrocyte glycoprotein antibody-associated disease with brain involvement: description of various cerebral syndromes.

Article References:

Choi, Y., Kim, W., Lim, B. et al. Neuroimaging spectrum of myelin oligodendrocyte glycoprotein antibody-associated disease with brain involvement: description of various cerebral syndromes.
Pediatr Radiol (2025). https://doi.org/10.1007/s00247-025-06342-y

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s00247-025-06342-y

Keywords: MOGAD, neuroimaging, cerebral syndromes, autoimmune disorder, MRI, demyelination.